Alaunos Therapeutics, Inc. · NASDAQ:TCRT
Alaunos Therapeutics — Ziopharm Oncology — Corporate Update (October 2018)
25 slides from Alaunos Therapeutics's corporate update, Oct 9, 2018
Slide 1: A New Day for Ziopharm Oncology
A New Day for Ziopharm Oncology October 9, 2018 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation contains certain forward-looking information about Ziopharm Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that
Slide 3: Agenda
Agenda (beginning 8 am ET October 9, 2018) On the Call Laurence Cooper, MD, PhD, CEO David Mauney, MD, EVP, CBO and Interim COO David Connolly, VP, Corporate Communications and IR Rob Hadfield, General Counsel Introduction / Overview Laurence Cooper Terms of New Agreement David Mauney Clinical Progr
Slide 4: The New Ziopharm
The New Ziopharm Ziopharm ONCOLOGY
Slide 5: The "New Ziopharm" with Full Autonomy
The “New Ziopharm” with Full Autonomy New Day for Ziopharm Oncology New, simplified licensing agreement with Intrexon/Precigen Preferred stock issued to Intrexon fully retired Revised Board of Directors Strategic flexibility for corporate development, sublicensing Aligned financial incentives and re
Slide 6: Refined Focus on Controlled IL-12 and Sleeping Beauty
Refined Focus on Controlled IL-12 Sleeping Beauty for All TCR Targets and Two CAR Targets New Day for Ziopharm Oncology Platform #1 Controlled IL-12 Platform #2 Sleeping Beauty Ad-RTS-hIL-12 plus veledimex for brain cancer, other solid tumors Monotherapy Combination with immune checkpoint inhibitors
Slide 7: The New Ziopharm: Terms of New Agreement
The New Ziopharm Terms of New Agreement
Slide 8: Historic Overview of Ziopharm and Intrexon Relationship
Historic Overview of Ziopharm and Intrexon Relationship New Day for Ziopharm Oncology January 2011 – Intrexon and Ziopharm enter into Exclusive Channel Collaboration (ECC)* agreement Established 50-50 share of net profits; Ziopharm is Intrexon’s exclusive oncology partner; Limited sub-licensing righ
Slide 9: New License for Exclusive Rights to Controlled IL-12, Sleeping Beauty TCRs and CD19-CAR
New License for Exclusive Rights to Controlled IL-12, Sleeping Beauty TCRs and Sleeping Beauty CD19-CAR New Day for Ziopharm Oncology Controlled IL-12 Platform Exclusive rights to Ad-RTS-hIL-12 plus veledimex Ziopharm gains optionality for next-generation technologies for RTS-IL-12 Sleeping Beauty P
Slide 10: Additional Terms of 2018 Licensing Agreement with Precigen
Additional Terms of 2018 Licensing Agreement with Precigen New Day for Ziopharm Oncology Preferred stock valued at approximately $156.9 million* retired R.J. Kirk resigns from Ziopharm Board of Directors Ziopharm retains collaboration with MD Anderson Cancer Center and the approximately $31.7 millio
Slide 11: The New Ziopharm: Clinical Programs Update
The New Ziopharm Clinical Programs Update
Slide 12: Focused on Controlled IL-12, Sleeping Beauty-TCRs and Two CAR Targets
Focused on Controlled IL-12, Sleeping Beauty-TCRs to Target Solid Tumors plus Two CAR Targets New Day for Ziopharm Oncology Sleeping Beauty: Non-viral genetic modification of TCR-T cells and CAR-T cells to infuse an immune response Monotherapy (expansion) P-O-C = “Point-of-Care” for very rapid manuf
Slide 13: Controlled IL-12 Platform for Brain Tumors
Controlled IL-12 Platform for Brain Tumors Monotherapy of Ad-RTS-hIL-12 + veledimex has shown improved survival benefit of 12.7 months median overall survival (mOS) in 15 patients*; Low-dose steroid use improved survival Adult: Phase 1 expansion cohort with 20 mg of veledimex underway to expand clin
Slide 14: Market Opportunity for IL-12 in rGBM
Market Opportunity for IL-12 in rGBM – Three Paths to Commercialization to be Explored New Day for Ziopharm Oncology ~70,000 new adult cases world wide each year 12,3901 new cases in the U.S. each year 14,5762 new cases in Europe each year Recurrence = 90% US – 11,1511 EU – 13,1182 http://www.abta.o
Slide 15: Status of IND for Third-Generation CD19-specific CAR-T Trial
Status of Investigational New Drug Application for Third-Generation Trial to Evaluate CD19-specific CAR-T Therapy Per disclosures in June and August 2018, FDA requested additional pre-clinical process development, placed clinical hold on IND Guidance update on “point-of-care” (“P-O-C”): FDA mandated
Slide 16: Market Opportunity for CD19-Specific CAR-T
Market Opportunity for CD19-Specific CAR-T New Day for Ziopharm Oncology Estimated new cases of lymphomas and leukemias in U.S.* Updated Data on Blood Cancers, 2018, Leukemia & Lymphoma Society CA Cancer J Clin. 2016 Sep 12 [Epub ahead of print] Non-Hodgkin lymphomas ~105,000 ~27,000 Chronic lymphoc
Slide 17: Sleeping Beauty Provides Manufacturing Solution for Autologous TCR-T Therapies
Sleeping Beauty Provides Manufacturing Solution for Autologous Personalized TCR-T Therapies Targeting Neoantigens for Each Patient Neoantigens à the key to targeting solid tumors Intracellular antigens that are unique to each patient’s cancer TCRs Neoantigens can only be recognized by TCRs (& not CA
Slide 18: T cells Targeting Neoantigens Have Demonstrated Clinical Success in Solid Tumors
T cells Targeting Neoantigens has Demonstrated Clinical Success in Solid Tumors (History on our Side) New Day for Ziopharm Oncology Clockwise from top left: Science. 2014 May 9;344(6184):641-5 Nat Med. 2018 Jun;24(6):724-730 N Engl J Med. 2016, Dec 8;375(23):2255-2262 J Immunol. 2013 Jun 15;190(12):
Slide 19: NCI Advancing Sleeping Beauty to Target Neoantigens in Solid Tumors
NCI Advancing Sleeping Beauty to Target Neoantigens in Solid Tumors with TCR-expressing T cells Preclinical Data Patient Data in 2019 Completed Clinical Protocol Validation Complete 4Q 2018 ZIOPHARM and Intrexon Announce CRADA with NCI CRADA IND for TCR-T to be submitted in 4Q 2018 (unaffected by CA
Slide 20: Ziopharm Will be First to Use Non-Viral Approach to Manufacture TCR-T
Ziopharm Will be First to Use Non-Viral Approach to Manufacture TCR-T New Day for Ziopharm Oncology Neoantigens Likely, best chance to target solid tumors TCR-T Sleeping Beauty Superior technology to commercialize TCR-T Undertaken using the cutting edge science at NCI
Slide 21: Market Opportunity for TCR-T in Solid Tumors
Market Opportunity for TCR-T in Solid Tumors New Day for Ziopharm Oncology Prospect of TCR-T dwarfs the opportunity for CAR-T Ziopharm Neoantigens Immune checkpoint inhibitors ( iCPI ) 10 to 30% activity Neoantigens Vaccine Improve iCPI Neoantigens TCR-T Target can be independent of iCPI Depends on
Slide 22: The New Ziopharm: New Day
The New Ziopharm New Day Ziopharm ONCOLOGY
Slide 23: Key Investment Highlights: Expected Milestones and Value Inflection Points
Key Investment Highlights: Expected Milestones and Value Inflection Points New Day for Ziopharm Oncology Large platform opportunities currently in clinic and more in 2019 Strategic autonomy Preferred stock retired Three new board members with 75+ years experience in life sciences New Ziopharm on Day
Slide 24: Corporate Contacts
Corporate Contacts David Connolly Vice President, Corporate Communications / Investor Relations Tel: +1 (617) 502-1881 Email: dconnolly@ziopharm.com Mike Moyer Vice President, Portfolio Strategy Tel : +1 (617) 765-3770 Email : mmoyer@ziopharm.com Brennan Doyle Managing Director SOLEBURY TROUT Tel: +
Slide 25: Ziopharm Oncology
Ziopharm ON C © IL OLN